Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy
(MedPage Today) -- The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis (PC) in BRCA1/2 mutation carriers, a large... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 5, 2022 Category: OBGYN Source Type: news

Trametinib: New Go-To for Low-Grade Serous Ovarian Carcinoma? Trametinib: New Go-To for Low-Grade Serous Ovarian Carcinoma?
For the first time, a randomized trial has reported positive results in patients with this particular type of ovarian cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 10, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trametinib Slows Recurrent Low-Grade Serous Ovarian Carcinoma
WEDNESDAY, Feb. 9, 2022 -- Trametinib may be a new option for standard-of-care treatment for recurrent low-grade serous ovarian carcinoma, according to a study published online Feb. 5 in The Lancet. David M. Gershenson, M.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 9, 2022 Category: Pharmaceuticals Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Systemic Therapy for Non-Serous Ovarian Carcinoma Systemic Therapy for Non-Serous Ovarian Carcinoma
The treatment of non-serous ovarian cancer requires a different approach. What are the available therapeutic options?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

One Strikeout, One Hit Against Low-Grade Serous Carcinomas One Strikeout, One Hit Against Low-Grade Serous Carcinomas
Two MEK inhibitors were tested against recurrent low-grade serous carcinomas of the ovaries, fallopian tubes, or peritoneum, but only one offered clinical benefit over standard care, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adavosertib Induces Tumor Shrinkage in 30% of Patients with Uterine Serous Carcinoma
A recent clinical trial ’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Gene signature found for poor response to standard chemotherapy in rare uterine cancer
(Medical College of Georgia at Augusta University) Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2020 Category: International Medicine & Public Health Source Type: news

Promising Efficacy With Adavosertib in Uterine Serous Carcinoma Promising Efficacy With Adavosertib in Uterine Serous Carcinoma
The experimental agent adavosertib showed hints of efficacy against recurrent uterine serous carcinoma in early data from a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological cancer with few effective, targeted therapies. HGSOC tumors exhibit genomic instability with frequent alterations in the protein kinome; however, only a small fraction of the kinome has been therapeutically targeted in HGSOC. Using multiplexed inhibitor beads and mass spectrometry, we mapped the kinome landscape of HGSOC tumors from patients and patient-derived xenograft models. The data revealed a prevalent signature consisting of established HGSOC driver kinases, as well as several kinases previously unexplored in HGSOC. Loss-of-function analysi...
Source: Signal Transduction Knowledge Environment - February 17, 2020 Category: Science Authors: Kurimchak, A. M., Herrera-Montavez, C., Brown, J., Johnson, K. J., Sodi, V., Srivastava, N., Kumar, V., Deihimi, S., OBrien, S., Peri, S., Mantia-Smaldone, G. M., Jain, A., Winters, R. M., Cai, K. Q., Chernoff, J., Connolly, D. C., Duncan, J. S. Tags: STKE Research Articles Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news